ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Iron

Also written as “PA21”, “PA21 (2.5 g tablet containing 500 mg iron)” and “CTX001 With Iron”.

Its studies are mostly in Hyperphosphatemia · Anemia · Renal Insufficiency, Chronic · Colorectal Neoplasms, led by 4 companies.

Drug pageIron: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 24, 201117 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL100 open or runningphase 3since Mar 24, 2011Jan 9, 2009none ahead
Kissei Pharmaceuticalits history only50 open or runningphase 3since Apr 12, 2013Jan 26, 2012none ahead
Cajal Therapeuticsits history only11 open or runningearly phase 1since May 5, 2026May 5, 2026none ahead
J. Uriachits history only10 open or runningphase 4since Sep 16, 2005Sep 16, 2005none ahead

Also a collaborator on its studies: Fresenius Medical Care.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSL only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2009First study: phase 2 study in Renal Insufficiency, ChronicFirst studyNCT00824460 · 154 enrolled · United States, Bulgaria, Croatia and more
  2. Mar 24, 2011Phase 3 study in Chronic Kidney Disease Requiring Chronic DialysisNCT01324128 · 1,059 enrolled · United States, Austria, Belgium and more
  3. Mar 25, 2011Phase 1 study in Drug Interaction PotentiationNCT01324752 · 36 enrolled · United States
  4. Sep 12, 2011Phase 3 study in Chronic Kidney Disease Requiring Chronic DialysisNCT01464190 · 659 enrolled · United States, Austria, Belgium and more
  5. Sep 16, 20112 phase 1 studies in HealthyNCT01438359, NCT01452906
  6. Nov 16, 20112 phase 1 studies in Drug Interaction PotentiationNCT01477424, NCT01477411
  7. Jul 5, 2017No phase study in AnemiaNCT03214627 · 88 enrolled · United Kingdom
  8. Aug 21, 2018Phase 3 study in HyperphosphatemiaNCT03644264 · 286 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 CSL leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03644264Hyperphosphatemia · China3CompletedAug 21, 2020286
NCT03214627Anemia · United Kingdom–TerminatedMay 21, 201988
NCT01477424Drug Interaction Potentiation · United States1CompletedFeb 201245
NCT01477411Drug Interaction Potentiation · United States1CompletedJan 201242
NCT01452906Healthy · United States1CompletedDec 201145
NCT01438359Healthy · United States1CompletedSep 201142
NCT01464190Chronic Kidney Disease Requiring Chronic Dialysis · United States, Austria, Belgium and more3CompletedOct 2012659
NCT01324752Drug Interaction Potentiation · United States1CompletedJun 201136
NCT01324128Chronic Kidney Disease Requiring Chronic Dialysis · United States, Austria, Belgium and more3CompletedApr 20121,059
NCT00824460Renal Insufficiency, Chronic · United States, Bulgaria, Croatia and more2CompletedOct 2009154

How it is read

Names in the registry

  • “PA21”, 11 entries
  • “PA21 (2.5 g tablet containing 500 mg iron)”, 2 entries
  • “CTX001 With Iron”, 1 entry
  • “IV iron”, 1 entry
  • “1.25 g PA21 (250 mg iron)”, 1 entry

Codes read as this program: PA21.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.